You are here: Industry Insights > ASC40

News List

Ascletis Announces First Patient Dosed in the Phase II Clinical Trial of FASN Inhibitor ASC40 for Treatment of Moderate to Severe Acne prnasia
January 14, 2022
Ascletis Pharma Inc. (HKEX: 1672) today announces the dosing of the first patient in the Phase II clinical trial of ASC40 for moderate to severe acne. ASC40 is an oral, selective inhibitor of fatty acid synthase (FASN)...
China NMPA Approves Phase II Clinical Trial of ASC40 for the Treatment of Patients with Acne prnasia
August 10, 2021
Ascletis Pharma Inc. announced that China National Medical Products Administration (NMPA) has approved the Phase II clinical trial application of ASC40 for the treatment of patients with moderate to severe acne.
China NMPA Approves Phase III Clinical Trial of ASC40 Combined with Bevacizumab for Treatment of Patients with Recurrent Glioblastoma prnasia
July 22, 2021
Ascletis Pharma Inc. today announces that China National Medical Products Administration (NMPA) has approved the Phase III clinical trial application of ASC40 combined with Bevacizumab for treatment of patients with recurrent glioblastoma.
Clinical Trial Application of ASC40 Combined with Bevacizumab to Treat Patients with Recurrent Glioblastoma Accepted by China NMPA prnasia
May 25, 2021
Ascletis Pharma Inc. today announces that following the consultation with China National Medical Products Administration (NMPA), the clinical trial application of ASC40 combined with bevacizumab to treat patients with recurrent glioblastoma (rGBM) has ...
Ascletis Announces Investment Escalation in R&D of Cancer Lipid Metabolism and Oral Checkpoint Inhibitors prnasia
March 30, 2021
Ascletis Pharma Inc. announces today that the board of directors of the Company has resolved to deploy more resources and investment in the R&D of cancer lipid metabolism and oral checkpoint inhibitors.
FASN Inhibitor ASC40 Demonstrates Positive Phase 2 Topline Clinical Results from China Cohort of Patients with NASH prnasia
March 09, 2021
Gannex Pharma Co., Ltd., a wholly-owned company of Ascletis Pharma Inc., and Sagimet Biosciences Inc. jointly announced today positive topline results from the China cohort of a Phase 2 randomized, placebo-controlled clinical trial of oral ...
ASC40 (TVB-2640) Phase 2 NASH Trial Completed Patient Enrollment in China prnasia
November 19, 2020
Gannex Pharma Co., Ltd., a wholly owned company of Ascletis Pharma Inc. and Sagimet Biosciences Inc. jointly announced today that they have completed patient enrollment in the ASC40 (TVB-2640) Phase 2 NASH trial in China.
Gannex receives US IND Approval for NASH drug candidate, an FXR agonist expresspharma
October 14, 2020
In two NASH animal models, ASC42 demonstrated significant improvements in liver steatosis, inflammation and fibrosis.
Bridging Study in China Completed for NASH Drug Candidate ASC40 prnasia
July 20, 2020
Ascletis Pharma Inc. (HKEX code: 1672) announces today that a single-dose, pharmacokinetic bridging study of non-alcoholic steatohepatitis (NASH) drug candidate ASC40 (TVB-2640) in 34 Chinese subjects has been completed and data indicates that key pharma
Ascletis receives IND approval for its NASH drug biospectrumasia
August 28, 2019
ASC40 is an orally bioavailable, first-in-class inhibitor of fatty acid synthase (FASN)